吉西他滨联合顺铂±维利帕尼治疗gBRCA/PALB2突变胰腺癌的随机II期试验
该随机多中心II期试验评估吉西他滨联合顺铂(A组)对比联合维利帕尼(B组)在携带gBRCA/PALB2突变的晚期胰腺导管腺癌患者中的疗效。结果显示两组客观缓解率分别为74.1%和65.2%,差异无统计学意义;结论认为顺铂联合吉西他滨是有效方案,加用维利帕尼未提高缓解率。
要点
- 顺铂联合吉西他滨在gBRCA/PALB2+晚期胰腺癌中客观缓解率达74.1%。
- 加用维利帕尼未显著改善缓解率或生存终点。
- 含维利帕尼组3-4级血液学毒性(血小板减少55% vs 9%)更高。
核心结论
- 顺铂联合吉西他滨是晚期gBRCA/PALB2+胰腺导管腺癌的有效方案。
- 同步加用维利帕尼未提高缓解率。
研究设计与样本
- 开放标签、随机、多中心、两臂II期试验。
- 纳入未经治疗、可测量III-IV期、ECOG体能状态0-1的gBRCA/PALB2+胰腺导管腺癌患者。
主要发现
- A组中位总生存15.5个月(95%CI 12.2-24.3),B组16.4个月(95%CI 11.7-23.4)(P=0.6)。
- 全队列2年总生存率30.6%(95%CI 17.8%-44.4%),3年总生存率17.8%(95%CI 8.1%-30.7%)。
关键数值与推荐
- A组3-4级中性粒细胞减少13例(48%),B组7例(30%)。
- A组3-4级血小板减少15例(55%),B组2例(9%)。
- A组3-4级贫血14例(52%),B组8例(35%)。
临床怎么用
- 对于gBRCA/PALB2+晚期胰腺癌,可考虑顺铂联合吉西他滨作为标准方案。
- 不推荐在顺铂联合吉西他滨基础上常规加用维利帕尼。
局限性
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Five percent to 9% of pancreatic ductal adenocarcinomas (PDACs) develop in patients with a germline BRCA1/2 or PALB2 (gBRCA/PALB2+) mutation. Phase IB data from a trial that used cisplatin, gemcitabine, and veliparib treatment demonstrated a high response rate (RR), disease control rate (DCR), and overall survival (OS) in this population. We designed an open-label, randomized, multicenter, two-arm phase II trial to investigate cisplatin and gemcitabine with or without veliparib in gBRCA/PALB2+ PDAC. PATIENTS AND METHODS: Eligible patients had untreated gBRCA/PALB2+ PDAC with measurable stage III to IV disease and Eastern Cooperative Oncology Group performance status of 0 to 1. Treatment for patients in arm A consisted of cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 intravenously on days 3 and 10; treatment for patients in arm B was the same as that for patients in arm A, and arm A also received veliparib 80 mg orally twice per day on days 1 to 12 cycled every 3 weeks. The primary end point was RRs of arm A and arm B evaluated separately using a Simon two-stage design. Secondary end points were progression-free survival, DCR, OS, safety, and correlative analyses. RESULTS: Fifty patients were evaluated by modified intention-to-treat analysis. The RR for arm A was 74.1% and 65.2% for arm B (P = .55); both arms exceeded the prespecified activity threshold. DCR was 100% for arm A and 78.3% for arm B (P = .02). Median progression-free survival was 10.1 months for arm A (95% CI, 6.7 to 11.5 months) and 9.7 months for arm B (95% CI, 4.2 to 13.6 months; P = .73). Median OS for arm A was 15.5 months (95% CI, 12.2 to 24.3 months) and 16.4 months for arm B (95% CI, 11.7 to 23.4 months; P = .6). Two-year OS rate for the entire cohort was 30.6% (95% CI, 17.8% to 44.4%), and 3-year OS rate was 17.8% (95% CI, 8.1% to 30.7%). Grade 3 to 4 hematologic toxicities for arm A versus arm B were 13 (48%) versus seven (30%) for neutropenia, 15 (55%) versus two (9%) for thrombocytopenia, and 14 (52%) versus eight (35%) for anemia. CONCLUSION: Cisplatin and gemcitabine is an effective regimen in advanced gBRCA/PALB2+ PDAC. Concurrent veliparib did not improve RR. These data establish cisplatin and gemcitabine as a standard approach in gBRCA/PALB2+ PDAC.
引用
- O'Reilly EM, Lee JW, Zalupski M, et al. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol. 2020. PMID: 31976786. doi:10.1200/JCO.19.02931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。